1 active not recruiting, 1 completed. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Primary Peritoneal Transitional Cell Carcinoma: new trials by email Literature Review of Primary Peritoneal Transitional Cell Carcinoma trials Research Report on Primary Peritoneal Transitional Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Biospecimen Collection, Computed Tomography, Echocardiography Test - Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 55 | 2020-05-07 | 2026-07-20 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
Fallopian Tube Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Adnexal Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Neoplasms by Site (1) · Ovarian Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Disulfides (1) · Doxorubicin (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · Taxes (1) · liposomal doxorubicin (1) · peposertib (1)
Mayo Clinic (1) · National Cancer Institute (NCI) (1)
United States (2)
Matthew S. Block, M.D., Ph.D. (1) · Rachel N Grisham (1)
UM1CA186691 (1)